Investing in Human 3 - the new epoch of health, wellbeing and performance

Investing in Human 3 - the new epoch of health, wellbeing and performance

Sam Tabone, Partner at XEIA joins Brom on the podcast to discuss XEIA's "Human 3" thesis.


Check out XEIA at https://www.xeiavp.com/


Timestamps

0:00 - why we created Human 3 - going from psychedelic medicine to the broader Human 3 space

8:00 - critiquing the Human 3 manifesto

12:00 regulatory and social drivers of Human 3

19:00 - what Human 3 is NOT

31:00 - what defines Human 3 / what Human 3 is?

50:00 - areas where Human 3 can make the biggest impact

58:00 - distribution shifting technologies 1:10:00 - how Human 3 is useful outside of Neuro

1:20:00 - closing thoughts


The Human 3 Manifesto:

Human 3: the new epoch of health, wellbeing and performance


While modern medicine (Human 2) benefited society in incalculable ways, it ultimately fell short of its promise because the available tools forced it to operate at an incremental pace with long feedback loops.Today, exponential technologies like AI - which can parse through terabytes of scientific literature and data in seconds - and brain-computer-interfaces, biosensors and CRISPR - which enable real-time, read-write access to our biology - promise to rapidly accelerate the scientific method flywheel and lead to an exponential explosion in health, wellness and performance.


Human 3 will elevate every area of health and wellbeing, but will have the biggest impact in areas where modern medicine has made the least progress: the mental health crisis, neurodegeneration, chronic disease and aging. These are the “focal points” of our investment strategy.


Human 3 is not a “sector” - our companies combine life sciences, AI, hardware, software, deep tech & health tech in novel ways that often defy conventional categorization. Human 3 is a philosophy of vitality. It is a knowing that the “user experience” of the human body and mind is long overdue for an upgrade. It is the willingness to build and invest in that future. This is Human 3.


This movement marks the third great epoch of human health:

  • Human 1 was defined by medieval practices like bloodletting and humorism - medicine before evidence.


  • Human 2 was the era of “modern” medicine, which began in the 1850s when Louis Pasteur popularized the germ theory of disease and the scientific method became the gold standard. Human 2 was constrained by both incremental tools and artificial boundaries between disciplines.


  • Human 3 builds on Human 2’s legacy of scientific rigour, but is accelerated by exponential technologies, transdisciplinary collaborations, and driven by a belief that we can do so much more to not just heal the sick, but to prevent illness in the first place and elevate the already healthy.

‍‍‍

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(32)

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Aug 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.​Psychedelic Biotechs like GH Research, Compass ...

30 Juli 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Juli 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Juli 20251h 33min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Juli 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Juli 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Juli 20251h

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

Arye Lipman is the cofounder of Biosphere, a startup that recently raised millions of dollars from Peter Thiel's Founders Fund and Chris Sacca's Lower Carbon Capital to Unleash Industrial Biomanufactu...

30 Juni 20251h 20min

Populärt inom Teknik

uppgang-och-fall
market-makers
bilar-med-sladd
elbilsveckan
skogsforum-podcast
rss-laddstationen-med-elbilen-i-sverige
rss-technokratin
natets-morka-sida
rss-elektrikerpodden
developers-mer-an-bara-kod
bli-saker-podden
gubbar-som-tjotar-om-bilar
rss-it-sakerhetspodden
rss-uppgang-och-fall
rss-veckans-ai
hej-bruksbil
har-vi-akt-till-mars-an
vi-bilagares-podcast
rss-powerboat-sverige-podcast
rss-snacka-om-ai